Dr Tien-Huey Lim

BHB (Auckland), MBChB (Auckland), MD (Auckland), FRACP

Consultant Gastroenterologist and Hepatologist

Areas of expertise:

-Endoscopy- diagnostic and therapeutic gastroscopy and colonoscopy

- Bowel cancer screening

- Functional bowel disease, dyspepsia, gastro-oesophageal reflux disease, irritable bowel syndrome (IBS) and inflammatory bowel disease

- Anaemia and GI bleeding (pillcam)

- Coeliac disease

- Liver disease: All liver disease, with particular subspecialist and research interest in Hepatitis B, Hepatitis C and fatty liver

- FIbroscan

Qualifications:

Degrees: BHB, MBChB (Auckland), FRACP, MD (University of Auckland)

Current employment:

Consultant gastroenterologist and general physician at Middlemore Hospital, 2013 to present

Additional language skills:

Mandarin, Cantonese, Teochew, Hokkien, Malay

Training:

Auckland University Medical School (1999-2004)

Advanced gastroenterology and hepatology training in Auckland Region (FRACP 2013)

Post graduate doctorate research fellowship in natural history of chronic hepatitis B (MD, University of Auckland)

Research:

Publications:

1)    Lim TH, Gane EJ, Orr DW. Oral L-ornithine-L-aspartate is safe and effective in patients with intractable hepatic encephalopathy- the NZ Liver Transplant Unit experience. Hepatol Int 2010; 4(1): 258 (pp583).

2)    Lim TH, Gane EJ, Orr DW. Paracetamol overdose: Determinants of outcome from a single centre, 10 year experience. Hepatol Int 2011; 5(1): 69(pp02-18).

3)    Lim TH, Gane EJ, Orr DW. Paracetamol overdose: Outcomes of patients with liver failure and assessment of criteria for liver transplantation. Hepatol Int 2011; 5(1): 69(pp02-19).

4)    Lim TH, Gane EJ, Moyes CD, Hornell J, Cunningham CW. The impact of childhood-acquired HBV infection in New Zealand Maori: Results of a case-controlled cohort study. Hepatology 2011; 54(4, supplement): 443A.

5)    Lim TH, Gane EJ, Moyes C, Cunningham C. Predictors of liver complications in childhood-acquired HBV infection in New Zealand Maori: Results of 27 year longitudinal study. J Hepatology 2012;56(supplement 2):S31.

6)    Lim TH, Wasywich CA, Ruygrok PN. A fatal case of magic mushroom ingestion in a heart transplant recipient. Int Med Journal 2012:42(11);1268-9.

7)    Lim TH, Gane EJ, Moyes CD, Borman B, Cunningham CW. Predictors of serologic and clinical outcomes in early horizontally acquired HBV genotype C and D infection in New Zealand Maori: results of a 28 year longitudinal study. Hepatology 2012;56(4 supplement):351A.

8)    Lim TH, Gane E, Moyes CD, Borman B, Cunningham CW. Serological and clinical outcomes of horizontally transmitted chronic hepatitis B infection in New Zealand Maori: results from a 28-year follow-up study. Gut 2015;64:966-72.

9)    Lim TH, Gane E, Moyes C, Borman B, Cunningham C. HBsAg loss in a New Zealand community study with 28-year follow up: rates, predictors and long-term outcomes. Hepatol Int 2016. Doi:10.1007/s12072-016-9709-6.

Research projects/Presentations: 

            2003/4 Summer Studentship with A/Prof Ed Gane (Hepatologist)- Lamivudine resistance in Hepatitis B patients in NZ

2005    Write up of case report on sarcoidosis and SVC obstruction

2007    Middlemore Hospital Medical Grand round presentation on Brachial neuritis

2008    Presented at Auckland Hospital Medical Grand round on pneumonia

2009    Presented at Auckland Hospital Grand round on Infliximab for IBD

2009    Presented at NZ Society of Gastroenterology Conference (Wellington)                  

a) Oral presentation on the use of LOLA for treatment of intractable hepatic encephalopathy

b) Poster presentation on management and outcomes of all patients admitted with ulcerative colitis from 2001 to 2008 in Auckland Hospital

c) Case presentation on management of Hepatitis C in liver transplant patients

d) Presented at Auckland Hospital Young Investigator Awards session on the use of LOLA for treatment of intractable hepatic encephalopathy

2010    a) Case presentation at NZ Hepatitis Conference (Whakatane) on challenges in screening and management of HCC in patients with chronic hepatitis B

            b) Poster presentation at APASL (Beijing) on effectiveness and safety of LOLA in the treatment of intractable hepatic encephalopathy

            c) Case presentation at Portal Hypertension workshop (Auckland) on intractable variceal bleeding

            d) Presentation at the NZ Society of Gastroenterology Conference (Auckland):

                - 2 oral presentations(i) Paracetamol overdose- 10 year outcomes at Auckland Hospital; and

                    (ii) Paracetamol overdose- outcomes of patients with liver synthetic dysfunction and assessments of criteria for liver transplantation

                     1 poster presentation on Endoscopic therapy for treatment of leaks post bariatric surgery- A case series from Middlemore Hospital

          e) Presented at Auckland Hospital Young Investigator Awards session on Paracetamol overdose- 10 year outcomes

2011  a) 2 poster presentations at APASL (Bangkok; February) on Paracetamol overdose

         b) Poster presentation at APDW (Singapore; October) on Endoscopic therapy for treatment of leaks post bariatric surgery- A case series from Middlemore Hospital

         c) Oral presentation at AASLD (San Francisco; November) on The Impact of childhood acquired hepatitis B infection in NZ Maori: Results of a case-controlled cohort study

         d) Oral presentation at NZSG conference (Dunedin; November) on The Impact of childhood acquired hepatitis B infection in NZ Maori: Results of a case-controlled cohort study- winner of the Roche Young Investigator Award             Hepatology prize

2012  a) Poster presentation at APASL (Taipei, February) on The impact of childhood acquired hepatitis B infection in NZ Maori

          b) Oral presentation at EASL (Barcelona; April) on Predictors of liver complications in childhood-acquired HBV infection in New Zealand Maori: Results of a 27 year longitudinal study

          c) Oral presentation at RACP/CSANZ meeting at Young Investigator Award session (Auckland, June) on The impact of childhood acquired hepatitis B infection in NZ Maori

          d) Case presentation at Gilead Hepatitis meeting (Auckland, June) on challenges in management of antiviral resistance in Hepatitis B

          e) Australasian Viral Hepatitis Meeting (Auckland, September):

            - Oral presentation on serologic and clinical outcomes of horizontally acquired hepatitis B infection in NZ Maori

            - Oral Poster presentation on the use of Fibroscan in assessment of chronic hepatitis B virus infection.

            - Poster presentation on Predictors of liver complications in childhood-acquired HBV infection in NZ Maori

          f) Poster presentation (AASLD, Boston; November): Predictors of serologic and clinical outcomes in early horizontally acquired HBV genotype C and D infection in New Zealand Maori: results of a 28 year longitudinal study

          g) Oral presentation in Young investigator’s award session (NZSG, Hamilton; November): Predictors of serologic and clinical outcomes in early horizontally acquired HBV infection in NZ Maori: Results from a 28 year longitudinal study- winner of the Roche Young Investigator Award Hepatology Prize

 

Clinical trials

CLINICAL TRIAL EXPERIENCE

DATES

TRIAL NAME

Role

Type

Phase

2017

AURORA 3152-301-002

(NASH)

Principal Investigator

Industry

3

2017

Novartis CLMB763X2201

(NASH)

Principal Investigator

Industry

2

2016

MONARCH Heparc-2008

(Hepatitis B)

Principal Investigator

Industry

2

2016

The REGENERATE study

(Non alcoholic steatohepatitis)

Principal Investigator

Industry

3

2016

ARC5211001

(Hepatitis B)

Principal Investigator

Industry

1a/1b

2012

P7977-2025

(Hepatitis C)

Sub-Investigator

Industry

2

2012

A1447028

(Hepatitis C)

Sub-Investigator

industry

3

2012

GS-US-334-018

(Hepatitis C)

Sub-Investigator

industry

3

2012

GS-US-248-0122  (Hepatitis C)

Sub-Investigator

observational

 

2012

M11-652

(Hepatitis C)

Sub-Investigator

industry

2

2011

MK-5172 and hepatic insufficiency

Sub-Investigator

industry

1

2011

H9H-MC-JBAK

(Hepatocellular cancer)

Sub-Investigator

Industry

2

2011

P7977-1231

(Hepatitis C)

Sub-Investigator

Industry

3

2011

GS-US-248-0121

(Hepatitis C)

Sub-Investigator

industry

2

2011

VX950-HEP-3002

(Hepatitis C)

Sub-Investigator

industry

3

2011

ANADYS (ANA598_505)

(Hepatitis C)

Sub-Investigator

industry

2

2011

PROMISE (TMC435HPC3007)

(Hepatitis C)

Sub-Investigator

industry

3

2011

QUEST-1 (TMC435-TiDP-C208) (Hepatitis C)

Sub-Investigator

industry

3

2011

ASPIRE (TMC435-C205)

(Hepatitis C)

Sub-Investigator

industry

2b

2011

LIGHT (Hepatocellular carcinoma)

Sub-Investigator

industry

3

2010

PP25195

(Hepatitis C)

Sub-Investigator

Industry

1

2010

SON OF NEPTUNE (MV22430) (Hepatitis B)

Sub-Investigator

industry

4

2009

SEARCH (Hepatocellular carcinoma)

Sub-Investigator

industry

3

2009

STORM (BAY 43-9006/12917) (Hepatocellular carcinoma)

Sub-Investigator

industry

3

2009

 

S-collate (MV22009)

(Hepatitis B)

Sub-Investigator

industry

3

2009

NP22660

(Hepatitis  C)

Sub-Investigator

industry

1

2009

GS-US-174-0121

(Hepatitis B)

Sub-Investigator

Industry

3b